MX350195B - Analogos de cistamina para el tratamiento de la enfermedad de parkinson. - Google Patents

Analogos de cistamina para el tratamiento de la enfermedad de parkinson.

Info

Publication number
MX350195B
MX350195B MX2013009608A MX2013009608A MX350195B MX 350195 B MX350195 B MX 350195B MX 2013009608 A MX2013009608 A MX 2013009608A MX 2013009608 A MX2013009608 A MX 2013009608A MX 350195 B MX350195 B MX 350195B
Authority
MX
Mexico
Prior art keywords
parkinson
disease
cystamine
treatment
analogues
Prior art date
Application number
MX2013009608A
Other languages
English (en)
Other versions
MX2013009608A (es
Inventor
Cicchetti Francesca
Rouillard Claude
Calon Frederic
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Publication of MX2013009608A publication Critical patent/MX2013009608A/es
Publication of MX350195B publication Critical patent/MX350195B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de análogos de cistamina para el tratamiento de la enfermedad de Parkinson. La presente invención también se refiere al uso de una composición que comprende análogos de cistamina y cisteína. La presente invención se refiere a un método para modificar el progreso de la enfermedad de Parkinson que comprende administrar una cantidad terapéuticamente efectiva de por lo menos un análogo de cistamina o una sal farmacéuticamente aceptable de un análogo de cistamina a un paciente necesitado del mismo.
MX2013009608A 2011-02-23 2012-02-23 Analogos de cistamina para el tratamiento de la enfermedad de parkinson. MX350195B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161445577P 2011-02-23 2011-02-23
CA2732440A CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease
PCT/CA2012/050106 WO2012113079A1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
MX2013009608A MX2013009608A (es) 2013-09-16
MX350195B true MX350195B (es) 2017-08-30

Family

ID=46717621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009608A MX350195B (es) 2011-02-23 2012-02-23 Analogos de cistamina para el tratamiento de la enfermedad de parkinson.

Country Status (11)

Country Link
US (1) US20140073694A1 (es)
EP (1) EP2678009B1 (es)
JP (1) JP6000985B2 (es)
KR (1) KR20140115239A (es)
CN (1) CN103442704A (es)
AU (1) AU2012220314B2 (es)
BR (1) BR112013021616A2 (es)
CA (1) CA2732440C (es)
MX (1) MX350195B (es)
RU (1) RU2630583C2 (es)
WO (1) WO2012113079A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
CN108289867A (zh) * 2015-07-02 2018-07-17 地平线孤儿病有限责任公司 Ado-抗性的半胱胺类似物和其用途
WO2017166139A1 (zh) 2016-03-30 2017-10-05 广东欧珀移动通信有限公司 中继传输的方法和装置
WO2020198529A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Ofcalifornia Substituted amino-thiol and amino-disulfide compounds, and uses thereof
US12576051B2 (en) * 2019-07-30 2026-03-17 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN119909064B (zh) * 2025-04-07 2025-08-15 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514942A1 (en) * 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Methods and compositions for the treatment of parkinson's disease and other a-synucleinopathies
RU2255775C1 (ru) * 2003-12-25 2005-07-10 Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук Способ лечения болезни паркинсона
ES2388310T7 (es) * 2006-01-27 2017-05-03 The Regents Of The University Of California Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
WO2008143876A2 (en) * 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration
EA201170018A1 (ru) * 2008-06-13 2011-08-30 Тева Фармасьютикал Индастриз, Лтд. Разагилин для изменения течения болезни паркинсона

Also Published As

Publication number Publication date
KR20140115239A (ko) 2014-09-30
CN103442704A (zh) 2013-12-11
EP2678009B1 (en) 2017-11-01
JP2014508758A (ja) 2014-04-10
US20140073694A1 (en) 2014-03-13
RU2013137645A (ru) 2015-02-20
WO2012113079A1 (en) 2012-08-30
JP6000985B2 (ja) 2016-10-05
EP2678009A1 (en) 2014-01-01
AU2012220314B2 (en) 2017-04-06
AU2012220314A1 (en) 2013-08-22
MX2013009608A (es) 2013-09-16
CA2732440C (en) 2017-10-31
CA2732440A1 (en) 2012-08-23
RU2630583C2 (ru) 2017-09-11
EP2678009A4 (en) 2014-08-06
BR112013021616A2 (pt) 2020-09-29

Similar Documents

Publication Publication Date Title
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington&#39;s disease
PH12012500968A1 (en) Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
PH12014500386A1 (en) Combination treatment for hepatitis c
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2013085849A3 (en) Sulfate esters of noribogaine
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson&#39;s disease
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция
TW201129361A (en) Methods for treating pain
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2014002817A (es) Suspension oral.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.

Legal Events

Date Code Title Description
FG Grant or registration